Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MGI Palonosetron Study Shows Superiority To GSK Zofran; User Fee In July

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

A pivotal study comparing MGI Pharma’s 5-HT3 antagonist palonosetron to GlaxoSmithKline’s market leader Zofran shows superior efficacy for palonosetron in prevention of chemotherapy-induced nausea and vomiting.

Related Content

MGI Aloxi approval
FDA NME Tally: Spring Thaw Brings Three March Approvals





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts